In young, non-cirrhotic HBV–HDV coinfection with minimal fibrosis on elastography, do you perform lifelong 6-month HCC surveillance based on HDV status alone, or do you modulate surveillance intensity based on fibrosis trajectory and treatment response?

It’s quite reasonable to be aggressive with HCC screening in a co-infection like this. It would also depend on whether you’re treating the hepatitis B, which would reduce the chances of HCC. And even more interesting is whether you’re treating the Delta with the new drug expected to be approved on M...

There are two separate issues.

1) the frequency of liver cancer stent with used to initiate. It is not dependent on the risk of cancer. It is related to the doubling times of cancer in ability to detect cancer when they are small, which is why a six months interval is always chosen.

2) while the rest ...